US and UK to reach agreement on eliminating tariffs for pharmaceuticals, announcement anticipated, sources report

LONDON, Dec 1 (Reuters) - The United Kingdom and the United States are expected to finalize an agreement eliminating tariffs on pharmaceutical products, with a formal announcement scheduled at the White House on Monday, according to sources familiar with the discussions.

Requests for comment from both the White House and the British government were not immediately answered.

In October, British Science Minister Patrick Vallance informed lawmakers that new, innovative medicines may face some price increases as part of the negotiations, whereas current drugs and generic medications are unlikely to experience similar adjustments.

U.S. President Donald Trump has urged European nations to pay higher prices for American pharmaceuticals. Meanwhile, leading drug companies have postponed investments in the UK, citing challenging market conditions.

Earlier this year, in May, the two governments agreed to pursue substantially preferential outcomes for pharmaceuticals, with Britain committing to enhance the operating environment for pharmaceutical companies within its borders.

(Reporting by Maggie Fick and Alistair Smout; Editing by Bernadette Baum)

Analysis: The UK-US Pharmaceutical Tariff Deal

The impending agreement between the United Kingdom and the United States to eliminate tariffs on pharmaceutical products represents a significant shift in the trade landscape. As reported, the formal announcement is expected at the White House on Monday, confirming the long-discussed deal. While the full details remain unclear, the agreement is likely to have wide-ranging implications for both nations' pharmaceutical markets.

In the lead-up to this announcement, there have been key statements from both sides. British Science Minister Patrick Vallance noted that new, innovative medicines might face some price hikes as part of the negotiations. However, generic drugs and existing medications are unlikely to see similar price adjustments. This seems to be a compromise aimed at addressing concerns over drug affordability while satisfying U.S. demands for higher prices on American pharmaceuticals in European markets.

From the U.S. perspective, President Donald Trump’s push for European countries to pay more for American drugs aligns with broader trade policies aimed at increasing U.S. revenue from exports. The British government, on the other hand, has been working to foster a more favorable environment for pharmaceutical companies, acknowledging that the industry is vital to the country's economy. However, these efforts have faced setbacks, as some leading drug manufacturers have postponed investments in the UK, citing difficult market conditions.

This new agreement could help stabilize the pharmaceutical sector by eliminating tariffs, but it also highlights the delicate balancing act both countries face. While Britain seeks to make its market more attractive to drug companies, it must also contend with rising drug costs that could put pressure on its healthcare system. On the U.S. side, the hope is that eliminating tariffs will pave the way for more lucrative exports, but this comes with the risk of exacerbating global tensions over pharmaceutical pricing.

Ultimately, the success of this deal will depend on how both countries navigate the complexities of drug pricing and market access. As the deal unfolds, it will be critical to monitor its impact on both the pharmaceutical industry and consumers in the UK and the U.S.

Sources:

• US, UK to agree to zero tariffs on pharmaceuticals, announcement expected, sources say